



Final Appraisal Recommendation
Advice No: 1121 – September 2021

Everolimus (Votubia®)
2 mg, 3 mg and 5 mg dispersible tablet

Submission by Novartis Pharmaceuticals UK Ltd

Recommendation of AWMSG

Everolimus (Votubia®) is recommended as an option for use within NHS Wales for the adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with tuberous sclerosis complex (TSC).

This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.

Additional note(s):

- Please refer to the Summary of Product Characteristics for the full licensed indication.
- AWMSG considered everolimus (Votubia®) as an orphan medicine according to the criteria in the AWMSG appraisal process for a medicine for a rare disease.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2142), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1121:
everolimus (Votubia®) 2 mg, 3 mg and 5 mg dispersible tablet, September 2021